Callan Capital LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,128 shares of the biopharmaceutical company’s stock, valued at approximately $209,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of HALO. Alps Advisors Inc. bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth about $344,000. Townsquare Capital LLC lifted its position in Halozyme Therapeutics by 21.9% during the third quarter. Townsquare Capital LLC now owns 44,175 shares of the biopharmaceutical company’s stock worth $1,687,000 after acquiring an additional 7,949 shares during the last quarter. Verity Asset Management Inc. boosted its holdings in shares of Halozyme Therapeutics by 22.5% during the third quarter. Verity Asset Management Inc. now owns 31,310 shares of the biopharmaceutical company’s stock worth $1,196,000 after acquiring an additional 5,741 shares during the period. Aurora Investment Counsel acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $1,347,000. Finally, EP Wealth Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $211,000. Institutional investors own 97.79% of the company’s stock.
Insider Activity at Halozyme Therapeutics
In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 109,755 shares in the company, valued at $5,488,847.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 40,000 shares of company stock valued at $1,858,100. 2.70% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Read Our Latest Report on HALO
Halozyme Therapeutics Price Performance
Shares of Halozyme Therapeutics stock traded up $0.08 on Wednesday, reaching $52.96. 1,586,709 shares of the stock were exchanged, compared to its average volume of 1,258,043. The firm’s 50 day moving average is $47.18 and its 200-day moving average is $41.14. The firm has a market cap of $6.74 billion, a PE ratio of 21.85, a P/E/G ratio of 0.53 and a beta of 1.27. The company has a debt-to-equity ratio of 8.44, a quick ratio of 5.36 and a current ratio of 6.64. Halozyme Therapeutics, Inc. has a one year low of $32.83 and a one year high of $54.35.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The firm had revenue of $195.88 million during the quarter, compared to analysts’ expectations of $201.72 million. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current fiscal year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Featured Stories
- Five stocks we like better than Halozyme Therapeutics
- Where Do I Find 52-Week Highs and Lows?
- This Stock’s Price Shifts Into High Gear With Analyst Upgrades
- Basic Materials Stocks Investing
- AI Boosts Glass Tech Leader Stock: Shares Up 75% and More to Come
- How Technical Indicators Can Help You Find Oversold StocksĀ
- AI Partnership Boosts This Top Tech Stock: Ready for More Gains?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.